DEDUCT | Database of Endocrine Disrupting chemicals and their Toxicity profiles

Bisphenol A

ToxCast endpoints for intended target type: RNA

Assay Name	Tissue	Organism	Target Gene ID	Target HGNC Symbol	Response	AC50 Value
CLD_CYP2B6_6hr	Liver	Human	1555	CYP2B6	Gain	0.77 μM
CLD_CYP3A4_48hr	Liver	Human	1576	CYP3A4	Gain	6.7 μM
LTEA_HepaRG_CYP1A1	Liver	Human	1543	CYP1A1	Activatory	11.68 μM
LTEA_HepaRG_ACOX1	Liver	Human	51	ACOX1	Inhibitory	0.08 μM
LTEA_HepaRG_CYP2C9	Liver	Human	1559	CYP2C9	Inhibitory	9.92 μM
LTEA_HepaRG_HSPA1A	Liver	Human	3303	HSPA1A	Activatory	0.01 μM
LTEA_HepaRG_MYC	Liver	Human	4609	MYC	Inhibitory	9.92 μM
LTEA_HepaRG_SDHB	Liver	Human	6390	SDHB	Activatory	0.0 μM
LTEA_HepaRG_SLCO1B1	Liver	Human	10599	SLCO1B1	Inhibitory	9.92 μM

ToxCast endpoints for intended target type: Protein

Assay Name	Tissue	Organism	Target Gene ID	Target HGNC Symbol	Response	AC50 Value
HCAN_AUR_hTPO	Kidney	Human	7173	TPO	Loss	0.31 μM
HCAN_AUR_hTPO	Kidney	Human	7173	TPO	Loss	0.76 μM
ATG_DR5_RAR_CIS	Liver	Human	5914\|5915\|5916	RARA\|RARB\|RARG	Activatory	0.29 μM
ATG_ERE_CIS	Liver	Human	2099	ESR1	Inhibitory	0.29 μM
ATG_PXRE_CIS	Liver	Human	8856	NR1I2	Activatory	1.97 μM
ATG_ERa_TRANS	Liver	Human	2099	ESR1	Gain	0.36 μM
ATG_PXR_TRANS	Liver	Human	8856	NR1I2	Gain	1.27 μM
ATG_RXRb_TRANS	Liver	Human	6257	RXRB	Gain	0.0 μM
CCTE_GLTED_hTBG		Human	6906	SERPINA7	Loss	10.09 μM
CCTE_GLTED_hTTR_0.125uM		Human	7276	TTR	Loss	5.5 μM
CCTE_Deisenroth_DEVTOX-GLR_Meso_SOX17	Pluripotent stem cell	Human	64321	SOX17	Gain
NVS_NR_hAR		Human	367	AR	Loss	9.86 μM
NVS_NR_hER		Human	2099	ESR1	Loss	0.3 μM
NVS_NR_hPPARa		Human	5465	PPARA	Loss	0.1 μM
NVS_NR_mERa		Mouse	13982	Esr1	Loss	2.03 μM
CCTE_Deisenroth_AIME_96WELL_LUC_Active	Mammary gland/breast	Human	2099	ESR1	Gain	0.62 μM
CCTE_Deisenroth_AIME_96WELL_LUC_Inactive	Mammary gland/breast	Human	2099	ESR1	Gain	0.6 μM
ATG_ERE_CIS	Liver	Human	2099	ESR1	Inhibitory	0.46 μM
ATG_PXRE_CIS	Liver	Human	8856	NR1I2	Activatory	5.8 μM
BSK_4H_VCAM1	Vascular	Human	7412	VCAM1	Inhibitory	8.73 μM
BSK_BE3C_IP10	Lung	Human	3627	CXCL10	Inhibitory	8.46 μM
BSK_BE3C_TGFb1	Lung	Human	7040	TGFB1	Inhibitory	5.42 μM
BSK_CASM3C_Thrombomodulin	Vascular	Human	7056	THBD	Inhibitory	8.01 μM
BSK_hDFCGF_VCAM1	Skin	Human	7412	VCAM1	Inhibitory	7.95 μM
BSK_LPS_PGE2	Vascular	Human	5732	PTGER2	Inhibitory	7.71 μM
BSK_SAg_CD40	Vascular	Human	958	CD40	Inhibitory	6.58 μM
ATG_DR5_RAR_CIS	Liver	Human	5914\|5915\|5916	RARA\|RARB\|RARG	Inhibitory	2.41 μM
ATG_ERE_CIS	Liver	Human	2099	ESR1	Inhibitory	0.1 μM
ATG_PXRE_CIS	Liver	Human	8856	NR1I2	Inhibitory	1.74 μM
ATG_ERa_TRANS	Liver	Human	2099	ESR1	Gain	0.09 μM
ATG_PXR_TRANS	Liver	Human	8856	NR1I2	Gain	0.67 μM
NVS_ADME_hCYP1A1		Human	1543	CYP1A1	Loss	5.22 μM
NVS_ADME_hCYP2C18		Human	1562	CYP2C18	Loss	7.43 μM
NVS_ADME_hCYP2C9		Human	1559	CYP2C9	Loss	4.37 μM
NVS_ADME_hCYP2J2		Human	1573	CYP2J2	Loss	4.93 μM
NVS_ADME_hCYP4F12		Human	66002	CYP4F12	Loss	4.07 μM
NVS_ADME_rCYP2A1		Rat	24894	Cyp2a1	Loss	3.3 μM
NVS_ADME_rCYP2A2		Rat	24895	Cyp2a2	Loss	2.35 μM
NVS_ADME_rCYP2C11		Rat	29277	Cyp2c11	Loss	1.1 μM
NVS_ADME_rCYP2C12		Rat	25011	Cyp2c12	Loss	10.0 μM
NVS_ADME_rCYP2C13		Rat	171521	Cyp2c13	Loss	3.87 μM
NVS_ADME_rCYP2D1		Rat	266684	Cyp2d1	Loss	10.0 μM
NVS_ADME_rCYP3A1		Rat	25642	Cyp3a23-3a1	Loss	9.88 μM
NVS_ADME_rCYP3A2		Rat	266682	Cyp3a2	Loss	7.75 μM
NVS_GPCR_h5HT6		Human	3362	HTR6	Loss	7.19 μM
NVS_GPCR_hOpiate_D1		Human	4985	OPRD1	Loss	11.92 μM
NVS_GPCR_hOpiate_mu		Human	4988	OPRM1	Loss	10.26 μM
NVS_NR_hAR		Human	367	AR	Loss	10.49 μM
NVS_NR_hCAR_Antagonist		Human	9970	NR1I3	Loss	0.15 μM
NVS_NR_hER		Human	2099	ESR1	Loss	0.69 μM
NVS_NR_hGR		Human	2908	NR3C1	Loss	4.77 μM
NVS_NR_mERa		Mouse	13982	Esr1	Loss	0.93 μM
NVS_NR_rAR	Prostate	Rat	24208	Ar	Loss	11.31 μM
NVS_TR_hDAT		Human	6531	SLC6A3	Loss	5.67 μM
NVS_TR_hNET		Human	6530	SLC6A2	Loss	5.73 μM
NVS_ADME_hCYP2B6		Human	1555	CYP2B6	Loss	12.09 μM
NVS_ADME_hCYP2C9		Human	1559	CYP2C9	Loss	4.9 μM
NVS_GPCR_h5HT6		Human	3362	HTR6	Loss	5.46 μM
NVS_GPCR_hAdoRA1	Brain	Human	134	ADORA1	Loss	0.87 μM
NVS_GPCR_hTXA2		Human	6915	TBXA2R	Loss	9.51 μM
NVS_NR_hAR		Human	367	AR	Loss	5.32 μM
NVS_NR_hER		Human	2099	ESR1	Loss	3.23 μM
NVS_NR_hPR		Human	5241	PGR	Loss	8.3 μM
NVS_NR_mERa		Mouse	13982	Esr1	Loss	0.79 μM
NVS_TR_gDAT	Brain	Guinea pig	100714898	Slc6a3	Loss	8.44 μM
NVS_TR_hDAT		Human	6531	SLC6A3	Loss	5.1 μM
NVS_GPCR_hTXA2		Human	6915	TBXA2R	Loss	5.04 μM
NVS_ADME_hCYP2C9		Human	1559	CYP2C9	Loss	4.7 μM
NVS_GPCR_gLTB4	Spleen	Guinea pig	100379538	Ltb4r	Loss	10.11 μM
NVS_GPCR_h5HT6		Human	3362	HTR6	Loss	1.95 μM
NVS_GPCR_hAdoRA1	Brain	Human	134	ADORA1	Loss	11.42 μM
NVS_GPCR_hOpiate_mu		Human	4988	OPRM1	Loss	11.15 μM
NVS_GPCR_hTXA2		Human	6915	TBXA2R	Loss	9.98 μM
NVS_GPCR_rOXT	Uterus	Rat	25342	Oxtr	Loss	7.41 μM
NVS_MP_rPBR	Kidney	Rat	24230	Tspo	Loss	6.73 μM
NVS_NR_hAR		Human	367	AR	Loss	5.19 μM
NVS_NR_hER		Human	2099	ESR1	Loss	1.81 μM
NVS_NR_hPR		Human	5241	PGR	Loss	10.67 μM
NVS_NR_mERa		Mouse	13982	Esr1	Loss	1.15 μM
NVS_OR_gSIGMA_NonSelective	Brain	Guinea pig	100135589	Sigmar1	Loss	5.06 μM
NVS_TR_hDAT		Human	6531	SLC6A3	Loss	6.3 μM
NVS_TR_rVMAT2	Brain	Rat	25549	Slc18a2	Loss	7.83 μM
BSK_BE3C_tPA	Lung	Human	5327	PLAT	Inhibitory	9.52 μM
BSK_LPS_PGE2	Vascular	Human	5732	PTGER2	Inhibitory	10.28 μM
BSK_BE3C_tPA	Lung	Human	5327	PLAT	Inhibitory	8.08 μM
BSK_SAg_CD69	Vascular	Human	969	CD69	Inhibitory	4.03 μM
BSK_hDFCGF_CollagenIII	Skin	Human	1281	COL3A1	Inhibitory	6.87 μM
BSK_LPS_TNFa	Vascular	Human	7124	TNF	Inhibitory	1.05 μM
ATG_ERE_CIS	Liver	Human	2099	ESR1	Inhibitory	0.32 μM
ATG_HIF1a_CIS	Liver	Human	3091	HIF1A	Inhibitory	178.94 μM
ATG_HSE_CIS	Liver	Human	3297	HSF1	Inhibitory	170.14 μM
ATG_ISRE_CIS	Liver	Human	3659	IRF1	Activatory	142.4 μM
ATG_PXRE_CIS	Liver	Human	8856	NR1I2	Inhibitory	4.61 μM
ATG_ERa_TRANS	Liver	Human	2099	ESR1	Gain	0.28 μM
ATG_PXR_TRANS	Liver	Human	8856	NR1I2	Gain	5.59 μM
ATG_BRE_CIS	Liver	Human	4086	SMAD1	Inhibitory	155.35 μM
ATG_E2F_CIS	Liver	Human	1869	E2F1	Inhibitory	151.72 μM
ATG_ERE_CIS	Liver	Human	2099	ESR1	Inhibitory	0.38 μM
ATG_HSE_CIS	Liver	Human	3297	HSF1	Inhibitory	183.53 μM
ATG_ISRE_CIS	Liver	Human	3659	IRF1	Inhibitory	158.7 μM
ATG_PBREM_CIS	Liver	Human	9970	NR1I3	Activatory	5.52 μM
ATG_PXRE_CIS	Liver	Human	8856	NR1I2	Activatory	6.22 μM
ATG_VDRE_CIS	Liver	Human	7421	VDR	Inhibitory	7.44 μM
ATG_ERa_TRANS	Liver	Human	2099	ESR1	Gain	0.32 μM
ATG_PXR_TRANS	Liver	Human	8856	NR1I2	Gain	4.66 μM
ATG_AP_2_CIS	Liver	Human	7020\|7021\|83741	TFAP2A\|TFAP2B\|TFAP2D	Inhibitory	148.37 μM
ATG_DR4_LXR_CIS	Liver	Human	7376\|10062	NR1H2\|NR1H3	Inhibitory	176.05 μM
ATG_ERE_CIS	Liver	Human	2099	ESR1	Activatory	0.36 μM
ATG_HSE_CIS	Liver	Human	3297	HSF1	Inhibitory	153.36 μM
ATG_IR1_CIS	Liver	Human	9971	NR1H4	Activatory	177.59 μM
ATG_ISRE_CIS	Liver	Human	3659	IRF1	Activatory	174.08 μM
ATG_PXRE_CIS	Liver	Human	8856	NR1I2	Activatory	4.48 μM
ATG_Xbp1_CIS	Liver	Human	7494	XBP1	Activatory	139.78 μM
ATG_ERa_TRANS	Liver	Human	2099	ESR1	Gain	0.22 μM
ATG_PXR_TRANS	Liver	Human	8856	NR1I2	Gain	3.58 μM
NVS_ADME_hCYP2C18		Human	1562	CYP2C18	Loss	6.02 μM
NVS_ADME_hCYP2C9		Human	1559	CYP2C9	Loss	5.42 μM
NVS_ADME_rCYP2A1		Rat	24894	Cyp2a1	Loss	4.43 μM
NVS_ADME_rCYP2A2		Rat	24895	Cyp2a2	Loss	3.35 μM
NVS_ADME_rCYP2C11		Rat	29277	Cyp2c11	Loss	1.81 μM
NVS_ADME_rCYP2C12		Rat	25011	Cyp2c12	Loss	4.05 μM
NVS_ADME_rCYP2C13		Rat	171521	Cyp2c13	Loss	4.44 μM
NVS_GPCR_g5HT4	Brain	Guinea pig	100135548	Htr4	Loss	10.38 μM
NVS_GPCR_gLTB4	Spleen	Guinea pig	100379538	Ltb4r	Loss	1.2 μM
NVS_NR_hCAR_Antagonist		Human	9970	NR1I3	Loss	0.09 μM
NVS_NR_hER		Human	2099	ESR1	Loss	0.52 μM
NVS_NR_hGR		Human	2908	NR3C1	Loss	3.64 μM
NVS_NR_mERa		Mouse	13982	Esr1	Loss	0.12 μM
NVS_NR_rAR	Prostate	Rat	24208	Ar	Loss	12.1 μM
NVS_ADME_rCYP2A1		Rat	24894	Cyp2a1	Loss	2.89 μM
NVS_ADME_rCYP2A2		Rat	24895	Cyp2a2	Loss	2.61 μM
NVS_ADME_rCYP2C11		Rat	29277	Cyp2c11	Loss	1.03 μM
NVS_ADME_rCYP2C12		Rat	25011	Cyp2c12	Loss	7.75 μM
NVS_ADME_rCYP2C13		Rat	171521	Cyp2c13	Loss	3.58 μM
NVS_NR_mERa		Mouse	13982	Esr1	Loss	0.26 μM
NVS_ADME_rCYP2A1		Rat	24894	Cyp2a1	Loss	2.56 μM
NVS_ADME_rCYP2A2		Rat	24895	Cyp2a2	Loss	2.18 μM
NVS_ADME_rCYP2C11		Rat	29277	Cyp2c11	Loss	0.72 μM
NVS_ADME_rCYP2C13		Rat	171521	Cyp2c13	Loss	2.96 μM
NVS_NR_hER		Human	2099	ESR1	Loss	0.24 μM
NVS_NR_rMR	Brain	Rat	25672	Nr3c2	Loss	12.09 μM
NVS_NR_hPXR		Human	8856	NR1I2	Loss	10.89 μM
NVS_TR_rVMAT2	Brain	Rat	25549	Slc18a2	Loss	8.27 μM
NVS_GPCR_h5HT6		Human	3362	HTR6	Loss	7.68 μM
NVS_TR_gDAT	Brain	Guinea pig	100714898	Slc6a3	Loss	6.86 μM
NVS_TR_rVMAT2	Brain	Rat	25549	Slc18a2	Loss	11.2 μM
NVS_NR_hPXR		Human	8856	NR1I2	Loss	8.08 μM
CCTE_Simmons_AUR_rTPO	Thyroid gland	Rat	54314	Tpo	Loss	1.17 μM
CCTE_Simmons_AUR_rTPO	Thyroid gland	Rat	54314	Tpo	Loss	0.37 μM
CCTE_Simmons_AUR_rTPO	Thyroid gland	Rat	54314	Tpo	Loss	0.53 μM
CCTE_Simmons_AUR_rTPO	Thyroid gland	Rat	54314	Tpo	Loss	1.0 μM
CCTE_Simmons_AUR_rTPO	Thyroid gland	Rat	54314	Tpo	Loss	1.34 μM
CCTE_Simmons_AUR_rTPO	Thyroid gland	Rat	54314	Tpo	Loss	1.37 μM
ATG_ERE_CIS	Liver	Human	2099	ESR1	Activatory	0.51 μM
ATG_PBREM_CIS	Liver	Human	9970	NR1I3	Inhibitory	7.46 μM
ATG_PXRE_CIS	Liver	Human	8856	NR1I2	Activatory	4.1 μM
ATG_VDRE_CIS	Liver	Human	7421	VDR	Activatory	10.54 μM
ATG_ERa_TRANS	Liver	Human	2099	ESR1	Gain	0.68 μM
ATG_PXR_TRANS	Liver	Human	8856	NR1I2	Gain	4.45 μM
ATG_ERE_CIS	Liver	Human	2099	ESR1	Inhibitory	0.26 μM
ATG_HSE_CIS	Liver	Human	3297	HSF1	Activatory	144.15 μM
ATG_PXRE_CIS	Liver	Human	8856	NR1I2	Activatory	3.43 μM
ATG_Xbp1_CIS	Liver	Human	7494	XBP1	Activatory	151.48 μM
ATG_ERa_TRANS	Liver	Human	2099	ESR1	Gain	0.7 μM
ATG_PXR_TRANS	Liver	Human	8856	NR1I2	Gain	4.04 μM
CCTE_Simmons_AUR_rTPO	Thyroid gland	Rat	54314	Tpo	Loss	0.34 μM
CCTE_Simmons_AUR_rTPO	Thyroid gland	Rat	54314	Tpo	Loss	0.43 μM
CCTE_Simmons_AUR_rTPO	Thyroid gland	Rat	54314	Tpo	Loss	0.45 μM
ATG_hERa_XSP1	Liver	Human	2099	ESR1	Gain	0.16 μM
ATG_hERb_XSP1	Liver	Human	2100	ESR2	Gain	0.27 μM
ATG_hERb_XSP2	Liver	Human	2100	ESR2	Gain	0.43 μM
ATG_hERa_XSP2	Liver	Human	2099	ESR1	Gain	0.3 μM
TOX21_ERa_BLA_Agonist_ratio	Kidney	Human	2099	ESR1	Gain	1.17 μM
TOX21_ERa_LUC_VM7_Agonist	Breast	Human	2099	ESR1	Gain	0.47 μM
TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881	Breast	Human	367	AR	Loss	9.66 μM
TOX21_ERb_BLA_Antagonist_ratio	Kidney	Human	2100	ESR2	Loss	2.78 μM
TOX21_PR_BLA_Antagonist_ratio	Kidney	Human	5241	PGR	Loss	10.74 μM
TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780	Breast	Human	2099	ESR1	Gain	12.26 μM
TOX21_ERa_BLA_Agonist_ratio	Kidney	Human	2099	ESR1	Gain	1.53 μM
TOX21_ERa_LUC_VM7_Agonist	Breast	Human	2099	ESR1	Gain	0.46 μM
TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881	Breast	Human	367	AR	Loss	9.58 μM
TOX21_ERb_BLA_Antagonist_ratio	Kidney	Human	2100	ESR2	Loss	3.37 μM
TOX21_PR_BLA_Antagonist_ratio	Kidney	Human	5241	PGR	Loss	11.52 μM

ToxCast endpoints for intended target type: Molecular messenger

Assay Name	Tissue	Organism	Target Gene ID	Target HGNC Symbol	Response	AC50 Value
CEETOX_H295R_ANDR	Adrenal gland	Human	367	AR	Inhibitory	3.1 μM
CEETOX_H295R_CORTIC	Adrenal gland	Human	2908\|4306	NR3C1\|NR3C2	Activatory	1.46 μM
CEETOX_H295R_TESTO	Adrenal gland	Human	367	AR	Inhibitory	3.57 μM
CEETOX_H295R_ANDR	Adrenal gland	Human	367	AR	Inhibitory	2.88 μM
CEETOX_H295R_ANDR	Adrenal gland	Human	367	AR	Activatory	3.26 μM
CEETOX_H295R_ANDR	Adrenal gland	Human	367	AR	Inhibitory	2.17 μM

ToxCast endpoints for intended target type: Pathway

Assay Name	Tissue	Organism	Target Gene ID	Target HGNC Symbol	Response	AC50 Value
ACEA_ER_80hr	Breast	Human	2099	ESR1	Gain	0.47 μM
ACEA_ER_80hr	Breast	Human	2099	ESR1	Gain	0.81 μM
ACEA_ER_80hr	Breast	Human	2099	ESR1	Gain	1.09 μM
ACEA_ER_80hr	Breast	Human	2099	ESR1	Gain	0.82 μM
ACEA_ER_80hr	Breast	Human	2099	ESR1	Gain	0.38 μM
ACEA_ER_80hr	Breast	Human	2099	ESR1	Gain	0.37 μM
APR_HepG2_P-H2AX_24hr	Liver	Human	3014	H2AX	Inhibitory	170.07 μM
ACEA_ER_80hr	Breast	Human	2099	ESR1	Gain	0.86 μM
ACEA_ER_80hr	Breast	Human	2099	ESR1	Gain	0.35 μM
ACEA_ER_80hr	Breast	Human	2099	ESR1	Gain	0.93 μM
OT_ER_ERaERa_0480	Kidney	Human	2099	ESR1	Gain	4.27 μM
OT_ER_ERaERa_1440	Kidney	Human	2099	ESR1	Gain	4.34 μM
OT_ER_ERaERb_0480	Kidney	Human	2099\|2100	ESR1\|ESR2	Gain	1.08 μM
OT_ER_ERaERb_1440	Kidney	Human	2099\|2100	ESR1\|ESR2	Gain	1.8 μM
OT_ER_ERbERb_0480	Kidney	Human	2100	ESR2	Gain	0.47 μM
OT_ER_ERbERb_1440	Kidney	Human	2100	ESR2	Gain	0.55 μM
OT_ERa_GFPERaERE_0120	Cervix	Human	2099	ESR1	Gain	0.69 μM
OT_ERa_GFPERaERE_0480	Cervix	Human	2099	ESR1	Gain	0.8 μM
OT_ER_ERaERa_0480	Kidney	Human	2099	ESR1	Gain	4.08 μM
OT_ER_ERaERa_1440	Kidney	Human	2099	ESR1	Gain	4.59 μM
OT_ER_ERaERb_0480	Kidney	Human	2099\|2100	ESR1\|ESR2	Gain	0.8 μM
OT_ER_ERaERb_1440	Kidney	Human	2099\|2100	ESR1\|ESR2	Gain	2.64 μM
OT_ER_ERbERb_0480	Kidney	Human	2100	ESR2	Gain	0.52 μM
OT_ER_ERbERb_1440	Kidney	Human	2100	ESR2	Gain	0.36 μM
OT_ERa_GFPERaERE_0120	Cervix	Human	2099	ESR1	Gain	1.06 μM
OT_ERa_GFPERaERE_0480	Cervix	Human	2099	ESR1	Gain	0.66 μM
OT_ER_ERaERa_0480	Kidney	Human	2099	ESR1	Gain	4.72 μM
OT_ER_ERaERa_1440	Kidney	Human	2099	ESR1	Gain	6.0 μM
OT_ER_ERaERb_0480	Kidney	Human	2099\|2100	ESR1\|ESR2	Gain	1.36 μM
OT_ER_ERaERb_1440	Kidney	Human	2099\|2100	ESR1\|ESR2	Gain	4.81 μM
OT_ER_ERbERb_0480	Kidney	Human	2100	ESR2	Gain	0.37 μM
OT_ER_ERbERb_1440	Kidney	Human	2100	ESR2	Gain	0.41 μM
OT_ERa_GFPERaERE_0120	Cervix	Human	2099	ESR1	Gain	0.86 μM
OT_ERa_GFPERaERE_0480	Cervix	Human	2099	ESR1	Gain	0.86 μM
OT_ER_ERaERb_0480	Kidney	Human	2099\|2100	ESR1\|ESR2	Gain	0.5 μM
OT_ER_ERaERb_1440	Kidney	Human	2099\|2100	ESR1\|ESR2	Gain	0.5 μM
OT_ER_ERbERb_0480	Kidney	Human	2100	ESR2	Gain	0.4 μM
OT_ER_ERbERb_1440	Kidney	Human	2100	ESR2	Gain	0.48 μM
OT_ERa_GFPERaERE_0120	Cervix	Human	2099	ESR1	Gain	0.49 μM
OT_ER_ERaERb_0480	Kidney	Human	2099\|2100	ESR1\|ESR2	Gain	0.32 μM
OT_ER_ERaERb_1440	Kidney	Human	2099\|2100	ESR1\|ESR2	Gain	0.41 μM
OT_ERa_GFPERaERE_0120	Cervix	Human	2099	ESR1	Gain	0.4 μM
OT_ERa_GFPERaERE_0480	Cervix	Human	2099	ESR1	Gain	0.81 μM
OT_ER_ERaERb_0480	Kidney	Human	2099\|2100	ESR1\|ESR2	Gain	0.58 μM
OT_ER_ERaERb_1440	Kidney	Human	2099\|2100	ESR1\|ESR2	Gain	0.49 μM
OT_ER_ERbERb_0480	Kidney	Human	2100	ESR2	Gain	0.42 μM
OT_ER_ERbERb_1440	Kidney	Human	2100	ESR2	Gain	0.46 μM
OT_ERa_GFPERaERE_0120	Cervix	Human	2099	ESR1	Gain	0.37 μM
OT_ERa_GFPERaERE_0480	Cervix	Human	2099	ESR1	Gain	0.85 μM

No ToxCast endpoints for intended target type: Cellular

No ToxCast endpoints for intended target type: Hormone

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.